Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a biotechnology company specializing in the discovery and development of cancer drugs. Its lead program, TNG908, is a synthetic lethal small molecule inhibitor targeting protein arginine methyltransferase 5 for cancers with methylthioadenosine phosphorylase deletions. The company also develops inhibitors for BRCA1 or BRCA2-mutant cancers and STK11-mutant cancers. Tango Therapeutics has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of cancer therapies.

Products

• TNG908 - synthetic lethal small molecule inhibitor

• Ubiquitin-specific protease 1 - inhibitor for BRCA1 or BRCA2-mutant cancers

• Target 3 - inhibitor for STK11-mutant cancers